AGEN AGENUS INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$5.58

Period return

+2.20 (+65.09%)

Volume

2.6M

2026-07-21O $5 H $5.9 L $4.99 C $5.58MA5 $5.11MA20 $3.93MA60 $3.6MA120 $3.53

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 10.Highin 20 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2025. 09. 10.LowBUY10 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 08. 28.LowBUY11 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 06. 04.LowHOLDlast year
Baird: Neutral
US analyst rating / recommendation change.
2025. 06. 04.MediumBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 05. 13.LowHOLDlast year
HC Wainwright & Co.: Neutral
US analyst rating / recommendation change.
2025. 05. 13.LowHOLDlast year
Baird: Neutral
US analyst rating / recommendation change.
2025. 04. 30.LowHOLDlast year
HC Wainwright & Co.: Neutral
US analyst rating / recommendation change.
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $15.5 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 10.	After market close (AMC)	$-0.4	—	—	$34M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-1.03	—	—	$24.07M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-8.65	—	—	$76.63M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-5.56	—	—	$51.51M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	170,922	$570.88K	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	117,117	$367.75K	0.00%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	108,220	$339.81K	0.00%	—	New position

AGENUS INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2025. 09. 10.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 08. 28.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 06. 04.	Baird	—	Maintain	Neutral → Neutral	—	Baird: Neutral
2025. 06. 04.	HC Wainwright & Co.	—	Upgrade	Neutral → Buy	—	HC Wainwright & Co.: Neutral → Buy
2025. 05. 13.	HC Wainwright & Co.	—	Maintain	Neutral → Neutral	—	HC Wainwright & Co.: Neutral
2025. 05. 13.	Baird	—	Maintain	Neutral → Neutral	—	Baird: Neutral